SCHEMBL6317671

SCHEMBL6317671

COc1ccccc1CNC(=O)c1c(-c2ccc(Br)s2)noc1N

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.52
ALDH1A1 P00352 5/20 0.47
HPGD P15428 4/20 0.47
KDM4E B2RXH2 1/20 0.47
RCE1 Q9Y256 1/20 0.47
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
HDAC1 Q13547 1/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HTT P42858 2/20 0.43
MAOB P27338 1/20 0.43
ADORA2A P29274 3/20 0.42
ADORA1 P30542 3/20 0.42
POLB P06746 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
ADORA2B P29275 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6315094 0.90 NPC1 (0.56) NPC1ALDH1A1HPGDKDM4ERCE1
SCHEMBL6323849 0.89 NPC1 (0.52) NPC1ALDH1A1HPGDKDM4ERCE1
SCHEMBL6323488 0.87 ALDH1A1 (0.45) NPC1ALDH1A1HPGDKDM4EHTT
SCHEMBL6323533 0.87 ALDH1A1 (0.47) NPC1ALDH1A1HPGDMAPTRXFP1
SCHEMBL6317499 0.85 HPGD (0.41) ALDH1A1HPGDMAPTMAOBADORA2A
SCHEMBL6318170 0.85 ALDH1A1 (0.45) NPC1ALDH1A1HPGDTP53MAPT
SCHEMBL6315227 0.84 HPGD (0.56) NPC1ALDH1A1HPGDKDM4ERCE1
SCHEMBL6317715 0.83 ADORA2A (0.42) TP53MAPTRXFP1MEN1KMT2A
SCHEMBL6323448 0.83 NTRK1 (0.43) HDAC1
SCHEMBL6324462 0.83 GAA (0.46) NPC1ALDH1A1HPGDTP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 NPC1 3741/4885ALDH1A1 4444/4885HPGD 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.